Article Sidebar

pdf
Date Published: 29/10/2025
Abstract Views: 76
Views pdf: 51
DOI: https://doi.org/10.51298/vmj.v555i1.15956
Issue
Vol. 555 No. 1 (2025)
Section
Các bài báo
How to Cite
Trần, H. Y., Hồ, H. T., & Dương, Q. H. (2025). THE ASSOCIATION BETWEEN PLASMA SEPTIN9 GENE METHYLATION STATUS AND CLINICAL TUMOR FEATURES IN HEPATOCELLULAR CARCINOMA PATIENTS. Vietnam Medical Journal, 555(1). https://doi.org/10.51298/vmj.v555i1.15956

THE ASSOCIATION BETWEEN PLASMA SEPTIN9 GENE METHYLATION STATUS AND CLINICAL TUMOR FEATURES IN HEPATOCELLULAR CARCINOMA PATIENTS

Hải Yến Trần, Hữu Thọ Hồ, Quang Huy Dương

Main Article Content

Abstract

Objective: To evaluate the association between plasma SEPTIN9 gene methylation (mSEPT9) with several tumor characteristics in patients with hepatocellular carcinoma (HCC). Subjects and Methods: This cross-sectional descriptive study was conducted on 133 patients with hepatocellular carcinoma (HCC) at the 103 Military Hospital. Plasma SEPTIN9 gene methylation was determined using the semi-nested real-time PCR technique. Results: Plasma mSEPT9 levels in HCC patients were significantly associated with the number of tumors (p = 0.01), tumor size ≥ 50 mm (p = 0.003), bilobar liver involvement (p < 0.0001), and the presence of portal vein thrombosis (p < 0.0001). The plasma mSEPT9 levels in patients with early-stage hepatocellular carcinoma (BCLC 0/A) were lower compared to those in patients with more advanced stages (BCLC B/C/D), with the difference being statistically significant (p < 0.05). Conclusion: Plasma SEPTIN9 gene methylation status is closely associated with tumor progression and disease stage in HCC patients, highlighting the potential of this non-invasive biomarker in diagnosis and prognosis.

Article Details

Keywords

Methylation SEPT9, hepatocellular carcinoma, semi-nested realtime PCR.

References

Filho A. M., Laversanne M., Ferlay J. et al. (2025). The GLOBOCAN 2022 cancer estimates: Data sources, methods, and a snapshot of the cancer burden worldwide. Int J Cancer, 156 (7), 1336-1346.
2. Llovet J. M., Kelley R. K., Villanueva A. et al. (2021). Hepatocellular carcinoma. Nat Rev Dis Primers, 7 (1), 6.
3. Villanueva A., Portela A., Sayols S. et al. (2015). DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 61 (6), 1945-1956.
4. Oussalah A., Rischer S., Bensenane M. et al. (2018). Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma. EBioMedicine, 30, 138-147.
5. Trần Quang Tú, Trần Công Duy Long, Đỗ Thị Hồng Tươi (2021). Đặc điểm bệnh nhân Ung thư biểu mô tế bào gan tại đơn vị ung thư gan mật và ghép gan - Khoa ngoại gan mật tụy Bệnh viện đại học Y Dược Thành phố Hồ Chí Minh. Tạp chí Y học Việt Nam, 504 (2), 20-25.
6. Kotoh Y., Suehiro Y., Saeki I. et al. (2020). Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun, 4 (3), 461-470.
7. Huang F., Yang G., Jiang H. et al. (2022). Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma. Technol Cancer Res Treat, 21, 15330338221144510.
8. Galasso L., Cerrito L., Termite F. et al. (2024). The Molecular Mechanisms of Portal Vein Thrombosis in Hepatocellular Carcinoma. Cancers, 16 (19), 3247.